AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- 1. (Currently Amended) A regime or regimen as defined by Claim 27, wherein said (i) aspartylglucosaminidase (AGA), and, optionally, said (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA), are is formulated into (iii) a topically applicable, physiologically acceptable medium therefor to form a topically applicable cosmetic/dermatological composition which is applied to said skin.
- 2-8. (Cancelled)
- 9. (Previously Presented) The regime or regimen as defined by Claim 1, wherein said aspartylglucosaminidase (AGA) comprises from 10⁻⁶ to 5% by weight of the composition.
- 10. (Previously Presented) The regime or regimen as defined by Claim 1, wherein said apartylglucosaminidase (AGA) comprises from 10⁻⁴ to 1% by weight of the composition.

- 11. (Previously Presented) The regime or regimen as defined by Claim 1, wherein said aspartylglucosaminidase (AGA) comprises from 0.001% to 0.1% by weight of the composition.
- 12. (Cancelled)
- 13. (Currently Amended) The regime or regimen as defined by Claim [[1]] 44, wherein said compound which stimulates the activity of aspartylglucosaminidase (AGA) the composition comprising sodium dodecyl sulfate or sodium lauryl ether sulfate comprises from 0.01% to 50% sodium dodecyl sulfate or sodium lauryl ether sulfate by weight of the composition.
- 14. (Currently Amended) The regime or regimen as defined by Claim 13, wherein said compound which stimulates the activity of aspartylglucosaminidase (AGA) the composition comprising sodium dodecyl sulfate or sodium lauryl ether sulfate comprises from 0.1% to 1% sodium dodecyl sulfate or sodium lauryl ether sulfate by weight of the composition.
- 15. (Cancelled)
- 16. (Previously Presented) The regime or regimen as defined by Claim 1, wherein said composition further comprises at least one other desquamating agent.

- 17. (Previously Presented) The regime or regimen as defined by Claim 16, wherein said composition further comprises at least one β-hydroxy acid; α-hydroxy acid; α- or β-keto acid; urea; gentisic acid; oligofucose; cinnamic acid; Saphora japonica extract; resveratrol or derivative thereof; glycosidase, *stratum corneum* chymotryptic enzyme (SCCE) or other serine or cysteine protease; chelating agent; aminosulphonic compound; sugar derivative; reducing agent and/or retinoid.
- 18.-20. (Cancelled)
- 21. (Previously Presented) The regime or regimen as defined by Claim 1, wherein said composition further comprises at least one moisturizing agent; propigmenting agent; agent stimulating the synthesis of dermal or epidermal macromolecules and/or preventing the degradation thereof; agent stimulating the proliferation or differentiation of keratinocytes; relaxing agent; antipollution and/or anti-free radical agent; UV-screening agent; permeating agent; or cicatrizing agent.
- 22.-23. (Cancelled)
- 24. (Currently Amended) A regime or regimen as defined by Claim 27 for promoting desquamation of the skin and/or for promoting hydration of the skin and for thus treating hyperkeratosis, xerosis, ichthyosis, psoriasis or reactive keratosis, comprising topically applying onto the skin of an individual in need of such treatment, a thus effective amount of (i) aspartylglucosaminidase (AGA), and, optionally, (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA).

- 25. (Currently Amended) A regime or regimen as defined by Claim 27 for promoting desquamation of the skin and/or for promoting hydration of the skin and for thus promoting cicatrization, comprising topically applying onto the skin of an individual in need of such treatment, a thus effective amount of (i) aspartylglucosaminidase (AGA), and, optionally, (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA).
- 26. (Cancelled)
- 27. (Currently Amended) A regime or regimen for promoting desquamation of the skin and/or for promoting hydration of the skin of an individual in need of such treatment, comprising topically applying thereon a thus effective amount of (i) aspartylglucosaminidase (AGA), and, optionally, (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA).
- 28. (Currently Amended) A regime or regimen as defined by Claim 27 for promoting desquamation of the skin and/or for promoting hydration of the skin and for thus facilitating the penetration into the skin of a cosmetic/dermatological active agent, comprising topically applying onto the skin of an individual in need of such treatment a thus effective amount of (i) aspartylglucosaminidase (AGA), and, optionally, (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA).

- 29. (Currently Amended) A regime or regimen as defined by Claim 27 for promoting desquamation of the skin and/or for promoting hydration of the skin and for thus combating bacterial adhesion to the skin, comprising topically applying onto the skin of an individual in need of such treatment, a thus effective amount of (i) aspartylglucosaminidase (AGA), and, optionally, (ii) at least one compound which stimulates the activity of aspartylglucosaminidase (AGA).
- 30.-42. (Cancelled)
- 43. (Currently Amended) The regime or regimen as defined by Claim 27, wherein said at least one compound which stimulates the activity of aspartylglucosaminidase (AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or sodium lauryl ether sulfate.
- 44. (Currently Amended) The regime or regimen as defined by Claim 1, wherein said at least one compound which stimulates the activity of aspartylglucosaminidase (AGA) is further comprising topically applying to the skin sodium dodecyl sulfate or sodium lauryl ether sulfate, wherein said sodium dodecyl sulfate or sodium lauryl ether sulfate is formulated into a topically applicable, physiologically acceptable medium therefor to form a topically applicable cosmetic/dermatological composition which is applied to said skin.
- 45. (Currently Amended) The regime or regimen as defined by Claim 16, wherein said at least one compound which stimulates the activity of aspartylglucosaminidase

Attorney's Docket No. 1016800-000583

Application No. 10/757,505

Page 7

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

46. (Currently Amended) The regime or regimen as defined by Claim 17, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

47. (Currently Amended) The regime or regimen as defined by Claim 21, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

48. (Currently Amended) The regime or regimen as defined by Claim 24, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

49. (Currently Amended) The regime or regimen as defined by Claim 25, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

Attorney's Docket No. 1016800-000583 Application No. 10/757,505

Page 8

50. (Currently Amended) The regime or regimen as defined by Claim 28, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

51. (Currently Amended) The regime or regimen as defined by Claim 29, wherein

said at least one compound which stimulates the activity of aspartylglucosaminidase

(AGA) is further comprising topically applying onto the skin sodium dodecyl sulfate or

sodium lauryl ether sulfate.

52-66. (Cancelled)

67. (New) A regime or regimen as defined by Claim 44 wherein said composition

comprising sodium dodecyl sulfate or sodium lauryl ether sulfate is applied together

with said composition comprising aspartylglucosaminidase (AGA).

68. (New) A regime or regimen as defined by Claim 44 wherein said composition

comprising sodium dodecyl sulfate or sodium lauryl ether sulfate is applied

separately from said composition comprising aspartylglucosaminidase (AGA).

69. (New) A regime or regimen as defined by Claim 44 wherein said composition

comprising sodium dodecyl sulfate or sodium lauryl ether sulfate is the same

composition comprising_aspartylglucosaminidase (AGA).